ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "IL6"

  • Abstract Number: 1247 • ACR Convergence 2021

    Plasma Cell-free DNA Is a Useful Biomarker for Tocilizumab Therapy in Rheumatoid Arthritis

    Teppei Hashimoto1, Yuichi Yokoyama2, Takahiro Yoshikawa3, Tetsuya Furukawa4, Naoto Azuma5, Akira Hashiramoto6 and Kiyoshi Matsui7, 1Hyogo College of Medicine, Kobe, Hyogo, Japan, 2Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, 3Hyogo College of Medicine, Nishinomiya, Japan, 4Hyogo college of Medicine, Nishinomiya, Hyogo, Japan, 5Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan, 6Kobe University, Kobe, Japan, 7Hyogo College of Medicine, Nishinomiya-city, Hyogo, Japan

    Background/Purpose: Endogenous DNA derived from nuclei is released into the blood circulation as cell-free DNA (cfDNA) following cell damage or death. cfDNA is associated with…
  • Abstract Number: 2397 • 2019 ACR/ARP Annual Meeting

    Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer

    Yoshinobu Koyama1, Akemi Senoo 2, Kaho Otsuki 3, Yoshiharu Sato 4, Mari Yamaguchi 2 and Toshie Higuchi 1, 1Center for Autoimmune Diseases, Division of Rheumatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, 2Division of Dermatology, Japanese Red Cross Okayama Hospital, Okayama, Japan, 3Center for Autoimmune Diseases, Division of Rheumatology, Okayama, Japan, 4DNA Chip Research Inc, Tokyo, Japan

    Background/Purpose: Skin lesion as a side effect of Tocilizumab (TCZ) has not been paid much attention. In the drug information sheets, incidence of dermatological adverse…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences